Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Han Zhao
Institutions:
National Clinical Research Center for Digestive Diseases,
Xijing Hospital,
Air Force Medical University
Observed institutions:
National Clinical Research Center for Digestive Diseases,
Fosun Pharma (China),
Xijing Hospital,
Air Force Medical University
ORCID:
0009-0007-7243-005X
Observed ORCID:
0009-0007-7243-005X
OpenAlex ID:
A5012257808
The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine
2025
·
Xinyi Men
, Yansheng Liu
, et al.
·
Clinical Reviews in Allergy & Immunology
·
15
PDF
Abstract P4-01-07: FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study
2023
·
Qiao Li
, Xian Wang
, et al.
·
Cancer Research
·
6
Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
2024
·
Gang Yuan
, Yili Chen
, et al.
·
International Journal of Clinical Practice
·
4
PDF
The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2– advanced breast cancer: Updated results from a phase 1b study.
2022
·
Jian Zhang
, Xiaojia Wang
, et al.
·
Journal of Clinical Oncology
·
1
Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study
2022
·
Lili Mao
, Jun Guo
, et al.
·
Cancer Research
Show more works
View as search
Works count:
5
Citation count:
26
H-index:
3
I10-index:
1
Year
Topic
Type